LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma

American Journal of Clinical Pathology
Dragan JevremovicEllen D McPhail

Abstract

The diagnosis of T-lymphoblastic leukemia/lymphoma (T-ALL) involving the thymus can be difficult to establish since neoplastic T lymphoblasts show significant phenotypic overlap with both normal thymocytes and thymocytes from epithelial thymic neoplasms (thymomas). LIM Domain Only 2 (LMO2) gene translocations have been implicated in the pathogenesis of a small subset of T-ALLs, and LMO2 protein has recently been reported to be expressed in a large proportion of T-ALLs. In this study, we tested specificity of LMO2 for distinction between neoplastic and nonneoplastic T-precursor cells in thymus and bone marrow. Our findings show that LMO2 is expressed in neoplastic lymphoblasts of T-ALL and is absent in thymocytes of normal thymuses or thymomas. LMO2 is therefore a useful marker for immunophenotypic assessment of thymic neoplasms.

References

Nov 2, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chang-Hoon Nam, Terence H Rabbitts
Jan 23, 2010·Science·Matthew P McCormackDavid J Curtis
Jan 11, 2013·Nature Reviews. Cancer·Jacqueline M MatthewsDavid J Curtis
Jan 28, 2014·PloS One·Stephen SmithUtpal P Davé
Sep 10, 2014·Applied Immunohistochemistry & Molecular Morphology : AIMM·Thomas MenterAlexandar Tzankov
Dec 18, 2014·The American Journal of Surgical Pathology·Armin G JegalianEric D Hsi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.